1. Home
  2. RTX vs NVS Comparison

RTX vs NVS Comparison

Compare RTX & NVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RTX Corporation

RTX

RTX Corporation

HOLD

Current Price

$194.61

Market Cap

275.1B

Sector

Industrials

ML Signal

HOLD

Logo Novartis AG

NVS

Novartis AG

HOLD

Current Price

$155.08

Market Cap

286.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RTX
NVS
Founded
1934
1895
Country
United States
Switzerland
Employees
N/A
75267
Industry
Aerospace
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
275.1B
286.9B
IPO Year
1994
N/A

Fundamental Metrics

Financial Performance
Metric
RTX
NVS
Price
$194.61
$155.08
Analyst Decision
Buy
Hold
Analyst Count
12
5
Target Price
$193.25
$144.00
AVG Volume (30 Days)
4.8M
2.1M
Earning Date
04-21-2026
04-28-2026
Dividend Yield
1.41%
2.02%
EPS Growth
39.72
N/A
EPS
4.96
N/A
Revenue
$80,738,000,000.00
N/A
Revenue This Year
$6.41
$2.56
Revenue Next Year
$6.65
$4.91
P/E Ratio
$38.84
$23.13
Revenue Growth
17.15
N/A
52 Week Low
$112.27
$97.72
52 Week High
$214.50
$170.46

Technical Indicators

Market Signals
Indicator
RTX
NVS
Relative Strength Index (RSI) 45.59 52.84
Support Level $193.07 $145.30
Resistance Level $205.41 $158.80
Average True Range (ATR) 4.62 2.23
MACD -1.17 0.16
Stochastic Oscillator 40.08 92.77

Price Performance

Historical Comparison
RTX
NVS

About RTX RTX Corporation

RTX is an aerospace and defense manufacturer formed from the merger of United Technologies and Raytheon, with roughly equal exposure across three segments, mostly as a supplier to commercial aerospace and to the defense market: Collins Aerospace, a diversified aerospace supplier; Pratt & Whitney, a commercial and military aircraft engine manufacturer; and Raytheon, a defense prime contractor providing a mix of missiles, missile defense systems, sensors, hardware, and communications technology to the military.

About NVS Novartis AG

Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.

Share on Social Networks: